Multidisciplinary support for young cancer survivors
Impact Evaluation of a Multidisciplinary End-of-treatment Day Hospital on the Quality of Life of Adolescents and Young Adults With Cancer
This study is testing whether a special support program can help young cancer survivors aged 15 to 25 feel better and improve their quality of life after finishing treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 214 (estimated) |
| Ages | 15 Years to 25 Years |
| Sex | All |
| Sponsor | Centre Leon Berard Academic / other |
| Locations | 1 site (Lyon) |
| Trial ID | NCT05858424 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the impact of a multidisciplinary day hospitalization program on the quality of life of adolescents and young adults who have completed cancer treatment. Participants aged 15 to 25 will be randomly assigned to either receive this specialized support or standard follow-up care. The study will assess changes in health-related quality of life, anxiety, depression, and emotional competence over the first year after treatment completion. The goal is to provide tailored support during a critical transition period for young cancer survivors.
Who should consider this trial
Good fit: Ideal candidates are adolescents and young adults aged 15 to 25 who have recently completed treatment for solid tumors or lymphoma.
Not a fit: Patients who are unable to participate in follow-up throughout the study duration or those who are incarcerated may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could significantly improve the quality of life and emotional well-being of young cancer survivors during their transition to post-treatment care.
How similar studies have performed: Other studies have shown promising results in improving quality of life for cancer survivors through multidisciplinary approaches, indicating potential success for this intervention.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Be aged between 15 and 25 years at diagnosis. This age range corresponds to the one chosen at the Leon Berard comprehensive cancer care center (CLB) for support in the AYA Department. 2. Be previously treated at the Paediatric Hematology and Oncology Institute (IHOPe) and/or at CLB in AYA Department 3. For a solid tumor or a lymphoma 4. Be in complete oncological response at the end of treatment; have received their end-of-treatment evaluation 5. Have finished their therapy since less than 2 months (therapy is defined by any treatment received, including maintenance) 6. Be capable of understanding, reading and writing French 7. Be affiliated to a health insurance plan 8. Have been informed of the study and have consented to it 9. For minor patients, consent of parents and/or legal tutors must be collected. Exclusion Criteria: 1. cannot be followed-up throughout the duration of the study (12 months), 2. be deprived of liberty by a court or administrative decision, 3. have not consent to participate or are incapable of objecting in an informed manner.
Where this trial is running
Lyon
- Centre Leon Berard — Lyon, France (Recruiting)
Study contacts
- Principal investigator: Amandine BERTRAND, MD — Institut d'Hématologie et d'Oncologie Pédiatrique
- Study coordinator: Amandine BERTRAND, MD
- Email: Amandine.BERTRAND@ihope.fr
- Phone: 04787872606
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.